AVOIDED COST IN COAGULATION FACTORS IN CONGENITAL COAGULOPATIES CLINICAL TRIALS

MT Rabuñal Álvarez, E Sánchez-Mira, P Sánchez-Carballo (pablo.sanchez.carballo@sergas.es), S Jimeno-Aguado, M Calvin-Lamas, S González-Piñeiro, MI Martín-Herranz.

Servicio de Farmacia - Complexo Hospitalario Universitario A Coruña. As Xubias, 84 15006 (A Coruña - Spain).

Background and Importance It is necessary know the profitability of clinical trials (CT) due to sponsors provided drugs free of charge, particularly in pathologies which have a high economic impact on hospital budget.

Aim and Objectives To quantify the avoided cost (AC) of coagulation factors derived from participation on congenital coagulopathies (CC) CT.

Materials and Methods Retrospective, observational study of CT conducted in CC at a tertiary hospital during 2022-2023.

\ For the calculation of AC, considered medicinal product and posology that patients received before enrollement in CT and doses they would have received if not enrolled.


Active CT during the study period in congenital coagulopathies



Data sources



CT management software Pharmacy service management database



Electronic medical records

Recorded data




Sponsor and study design



Patients included/CT



Time elapsed from inclusion in the CT to the prescription of a new treatment



Pathology



Prior treatment (medicinal product and posology) before enrollement in the CT




Cost of priot treatment (laboratory purchase price [LPP] + value added tax applied discounts on LPP)




5 CT in CC were carried out between 2022-2023



1/5 CT excluded for not recruiting patients



4/4 included CT open and sponsored by the pharmaceutical industry



Damaged surface (Intrinsic) pathway

Damaged sur



5 patients were enrolled (range 1-2) 5/5 diagnosed severe hemophilia A



Standard half-life (SHL) factor VIII (FVIII) in 3 patients Extended half-life (EHL) FVIII in 2 patients



Total AC: 829,545€

AC in SHL FVIII: 491,650€

AC in EHL FVIII: 337,896€

The total expenditure on FVIII in our hospital between 2022-2023 was 2,065,202€ for SHL FVIII and 4,771,999€ for EHL FVIII, so the 4 included CT represented 23.8% and 7.1% economic savings for hospital, respectively, on the total expense

> Average AC/CT: 207,386€ (range: 77,064€-453,980€)

> Average AC/patient: 165,909€ (range: 77,064€-260,832€)

Conclusion and Relevance Avoided cost of medications associated with participation in CT contributes to the sustainability of the healthcare system. Also, CT increase scientific knowledge and allow early access for patients to innovative treatments.



ÁREA SANITARIA DA CORUÑA E CEE

4CPS-018

